Bioactive Glass as Bone Graft Substitute in Operative Treatment of Bone - a 10 Years Follow-up Study

Vivoxid

Status: Completed

Conditions: Benign Bone Tumour Cavity; Spinal Fusion; Depressed Lateral Condyle Fracture

Treatments: Device: Bioactive glass and/or autogenous bone

Study type: Observational

Funder types: Industry

Identifiers

NCT00935870

1005-3

Details and patient eligibility

About

The main aim is to evaluate the long-term safety and bone healing in the operated area and to compare bioactive glass granules with autogenous bone as a filler material.

Enrollment: 63 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent obtained; Participation of previous clinical investigation with bioactive glass

Exclusion criteria

• The subject is unlikely to adhere to study procedures
• Concurrent disease or condition that in the opinion of the investigator is contraindicating participation
• Simultaneous participation in another medical device or investigational drug trial

Trial design

63 participants in 3 patient groups

A

Description:

DEPRESSED LATERAL CONDYLE FRACTURE

Treatment:

Device: Bioactive glass and/or autogenous bone

B

Description:

BENIGN BONE TUMOR

Treatment:

Device: Bioactive glass and/or autogenous bone

C

Description:

SPINAL FUSION

Treatment:

Device: Bioactive glass and/or autogenous bone